Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice

Experimental Neurology

Volumn 224, Issue 2, 2010, Pages 472-485

  Boimel, Moran ^a   Grigoriadis, Nikolaos ^b   Lourbopoulos, Athanasios ^b   Haber, Esther ^a   Abramsky, Oded ^a   Rosenmann, Hanna ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b AHEPA UNIVERSITY HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN D; CATHEPSIN L; FREUND ADJUVANT; IMMUNOGLOBULIN; PERTUSSIS TOXIN; PROTEIN ANTIBODY; TAU PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; IMMUNIZATION; IMMUNOREACTIVITY; MICROGLIA; MOUSE; NEUROFIBRILLARY TANGLE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TOXICITY TESTING;

ANIMALS; ANTIBODIES; ASTROCYTES; BRAIN; CATHEPSIN D; CATHEPSIN L; ENCEPHALITIS; FEMALE; IMMUNIZATION; LYSOSOMES; MICE; MICE, TRANSGENIC; MICROGLIA; NEUROFIBRILLARY TANGLES; NEURONS; PEPTIDE FRAGMENTS; PEPTIDE HYDROLASES; PHOSPHOPROTEINS; TAU PROTEINS; TAUOPATHIES; VACCINES, SYNTHETIC;

EID: 77954656871     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2010.05.010     Document Type: Article

References (43)

1. Asuni A.A., Boutajangout A., Quartermain D., Sigurdsson E.M. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J. Neurosci. 2007, 27:9115-9129.
2. Banks W.A. Are the extracellular [correction of extracelluar] pathways a conduit for the delivery of therapeutics to the brain?. Curr. Pharm. Des. 2004, 10:1365-1370.
3. Berger Z., Ravikumar B., Menzies F.M., Oroz L.G., Underwood B.R., Pangalos M.N., Schmitt I., Wullner U., Evert B.O., O'Kane C.J., Rubinsztein D.C. Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum. Mol. Genet. 2006, 15:433-442.
4. Boimel M., Grigoriadis N., Lourbopoulos A., Rozenstein L., Touloumi O., Mizrachi R., Abramsky O., Rosenmann H. Inflammation in the CNS increases Alzheimer's disease related neurofibrillary tangle burden: a study of experimental autoimmune encephalomyelitis in a transgenic animal model for neurofibrillary tangles. Neurology 2006, 66:279.
5. Boimel M., Grigoriadis N., Lourbopoulos A., Touloumi O., Rosenmann D., Abramsky O., Rosenmann H. Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy. J. Neuropathol. Exp. Neurol. 2009, 68:314-325.
6. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. (Berl) 1991, 82:239-259.
7. Dalmau J., Furneaux H.M., Rosenblum M.K., Graus F., Posner J.B. Detection of the anti-Hu antibody in specific regions of the nervous system and tumor from patients with paraneoplastic encephalomyelitis/sensory neuronopathy. Neurology 1991, 41:1757-1764.
8. Duyckaerts C., Delatour B., Potier M.C. Classification and basic pathology of Alzheimer disease. Acta Neuropathol. 2009, 118:5-36.
9. Ekinci F.J., Shea T.B. Phosphorylation of tau alters its association with the plasma membrane. Cell Mol. Neurobiol. 2000, 20:497-508.
10. Elliott E., Atlas R., Lange A., Ginzburg I. Brain-derived neurotrophic factor induces a rapid dephosphorylation of tau protein through a PI-3 kinase signalling mechanism. Eur. J. Neurosci. 2005, 22:1081-1089.
11. Fabian R.H. Uptake of antineuronal IgM by CNS neurons: comparison with antineuronal IgG. Neurology 1990, 40:419-422.
12. Fabian R.H., Petroff G. Intraneuronal IgG in the central nervous system: uptake by retrograde axonal transport. Neurology 1987, 37:1780-1784.
13. Ferrer I., Boada Rovira M., Sanchez Guerra M.L., Rey M.J., Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol. 2004, 14:11-20.
14. Furlan R., Brambilla E., Sanvito F., Roccatagliata L., Olivieri S., Bergami A., Pluchino S., Uccelli A., Comi G., Martino G. Vaccination with amyloid-beta peptide induces autoimmune encephalomyelitis in C57/BL6 mice. Brain 2003, 126:285-291.
15. Gallyas F. Silver staining of Alzheimer's neurofibrillary changes by means of physical development. Acta Morphol. Acad. Sci. Hung. 1971, 19:1-8.
16. Goedert M., Jakes R., Vanmechelen E. Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205. Neurosci. Lett. 1995, 189:167-169.
17. Holmes C., Boche D., Wilkinson D., Yadegarfar G., Hopkins V., Bayer A., Jones R.W., Bullock R., Love S., Neal J.W., Zotova E., Nicoll J.A. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008, 372:216-223.
18. Irony-Tur-Sinai M., Grigoriadis N., Lourbopoulos A., Pinto-Maaravi F., Abramsky O., Brenner T. Amelioration of autoimmune neuroinflammation by recombinant human alpha-fetoprotein. Exp. Neurol. 2006, 198:136-144.
19. Ishizawa K., Dickson D.W. Microglial activation parallels system degeneration in progressive supranuclear palsy and corticobasal degeneration. J. Neuropathol. Exp. Neurol. 2001, 60:647-657.
20. Kaye J.F., Kerlero de Rosbo N., Mendel I., Flechter S., Hoffman M., Yust I., Ben-Nun A. The central nervous system-specific myelin oligodendrocytic basic protein (MOBP) is encephalitogenic and a potential target antigen in multiple sclerosis (MS). J. Neuroimmunol. 2000, 102:189-198.
21. Kenessey A., Nacharaju P., Ko L.W., Yen S.H. Degradation of tau by lysosomal enzyme cathepsin D: implication for Alzheimer neurofibrillary degeneration. J. Neurochem. 1997, 69:2026-2038.
22. Kitazawa M., Oddo S., Yamasaki T.R., Green K.N., LaFerla F.M. Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J. Neurosci. 2005, 25:8843-8853.
23. Li Y., Liu L., Barger S.W., Griffin W.S. Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. J. Neurosci. 2003, 23:1605-1611.
24. Lourbopoulos A., Grigoriadis S., Symeonidou C., Deretzi G., Taskos N., Shohami E., Grigoriadis N. Modified Bielschowsky silver impregnation combined with hematoxylin or cresyl violet counterstaining as a potential tool for the simultaneous study of inflammation and axonal injury in the central nervous system. Aristotle Univer. Med. J. 2007, 34:31-40.
25. Masliah E., Hansen L., Adame A., Crews L., Bard F., Lee C., Seubert P., Games D., Kirby L., Schenk D. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 2005, 64:129-131.
26. Masliah E., Rockenstein E., Adame A., Alford M., Crews L., Hashimoto M., Seubert P., Lee M., Goldstein J., Chilcote T., Games D., Schenk D. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 2005, 46:857-868.
27. Mercken M., Vandermeeren M., Lubke U., Six J., Boons J., Van de Voorde A., Martin J.J., Gheuens J. Monoclonal antibodies with selective specificity for Alzheimer Tau are directed against phosphatase-sensitive epitopes. Acta Neuropathol. 1992, 84:265-272.
28. Monsonego A., Imitola J., Petrovic S., Zota V., Nemirovsky A., Baron R., Fisher Y., Owens T., Weiner H.L. Abeta-induced meningoencephalitis is IFN-gamma-dependent and is associated with T cell-dependent clearance of Abeta in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:5048-5053.
29. Nakanishi H. Neuronal and microglial cathepsins in aging and age-related diseases. Ageing Res. Rev. 2003, 2:367-381.
30. Nicoll J.A., Wilkinson D., Holmes C., Steart P., Markham H., Weller R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 2003, 9:448-452.
31. Oddo S., Billings L., Kesslak J.P., Cribbs D.H., LaFerla F.M. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 2004, 43:321-332.
32. Orgogozo J.M., Gilman S., Dartigues J.F., Laurent B., Puel M., Kirby L.C., Jouanny P., Dubois B., Eisner L., Flitman S., Michel B.F., Boada M., Frank A., Hock C. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003, 61:46-54.
33. Rosenmann H., Grigoriadis N., Karussis D., Boimel M., Touloumi O., Ovadia H., Abramsky O. Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Arch. Neurol. 2006, 63:1459-1467.
34. Rosenmann H., Meiner Z., Geylis V., Abramsky O., Steinitz M. Detection of circulating antibodies against tau protein in its unphosphorylated and in its neurofibrillary tangles-related phosphorylated state in Alzheimer's disease and healthy subjects. Neurosci. Lett. 2006, 410:90-93.
35. Rosenmann H., Grigoriadis H., Eldar-Levy H., Avital A., Rozenstein L., Touloumi O., Behar L., Ben-Hur T., Avraham Y., Eliot B., Menahem S., Ginzburg I., Abramsky O. A novel transgenic mouse expressing double mutant tau driven by its naturalpromoter exhibits tauopathy characteristics. Exp. Neurol. 2008, 212:71-84.
36. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400:173-177.
37. Shein N.A., Grigoriadis N., Alexandrovich A.G., Simeonidou C., Lourbopoulos A., Polyzoidou E., Trembovler V., Mascagni P., Dinarello C.A., Shohami E. Histone deacetylase inhibitor ITF2357 is neuroprotective, improves functional recovery, and induces glial apoptosis following experimental traumatic brain injury. FASEB J. 2009, 23:4266-4275.
38. Tampellini D., Magrane J., Takahashi R.H., Li F., Lin M.T., Almeida C.G., Gouras G.K. Internalized antibodies to the Abeta domain of APP reduce neuronal Abeta and protect against synaptic alterations. J. Biol. Chem. 2007, 282:18895-18906.
39. Wang Y., Martinez-Vicente M., Kruger U., Kaushik S., Wong E., Mandelkow E.M., Cuervo A.M., Mandelkow E. Tau fragmentation, aggregation and clearance: the dual role of lysosomal processing. Hum. Mol. Genet. 2009, 18:4153-4170.
40. Wilms H., Hartmann D., Sievers J. Ramification of microglia, monocytes and macrophages in vitro: influences of various epithelial and mesenchymal cells and their conditioned media. Cell Tissue Res. 1997, 287:447-458.
41. Wong E.S., Tan J.M., Soong W.E., Hussein K., Nukina N., Dawson V.L., Dawson T.M., Cuervo A.M., Lim K.L. Autophagy-mediated clearance of aggresomes is not a universal phenomenon. Hum. Mol. Genet. 2008, 17:2570-2582.
42. Zhang J.Y., Peng C., Shi H., Wang S., Wang Q., Wang J.Z. Inhibition of autophagy causes tau proteolysis by activating calpain in rat brain. J. Alzheimers Dis. 2009, 16:39-47.
43. Zheng-Fischhofer Q., Biernat J., Mandelkow E.M., Illenberger S., Godemann R., Mandelkow E. Sequential phosphorylation of Tau by glycogen synthase kinase-3beta and protein kinase A at Thr212 and Ser214 generates the Alzheimer-specific epitope of antibody AT100 and requires a paired-helical-filament-like conformation. Eur. J. Biochem. 1998, 252:542-552.